Posters

Outcome of 27 gauge microincision vitrectomy surgery for vitreo retinal diseases

Poster Details

First Author: M.Awan PAKISTAN

Co Author(s):                                 

Abstract Details



Purpose:

To report our experience, clinical outcome and safety profile of 27 gauge pars plana vitrectomy (PPV) in eyes with vitreo-retinal disease.

Setting:

Tertiary care Hospital

Methods:

Retrospective, single centre and interventional case series that included the eyes who underwent 27 gauge transconjunctival 3 ports PPV for different vitro-retinal diseases. The patients who had significant cataract, also had phacoemulsification cataract surgery at the same time. The outcome measures included change in visual acuity, intraoperative and postoperative complications with minimum follow up of 3 months.

Results:

Fifty one eyes met the inclusion criteria. Surgical indications included epiretinal membrane (n = 11), diabetic tractional retinal detachment (n = 12), full-thickness macular hole (n = 9), rhegmatogenous retinal detachment with (n = 2) or without (n = 3) proliferative vitreoretinopathy (PVR), vitreous haemorrhage (n = 10), endophthalmitis (n = 1), retained lens material (n = 1) and vireo-macular traction (n = 1). Mean LogMAR visual acuity improved from 1.02 ± 0.67 (20/ 210 Snellen equivalent) preoperatively to 0.50 ± 0.61 (20/63) Snellen equivalent) postoperatively (P < .001). Mean follow-up was 125 days (median 113 days, range 90–244 days). There were no intraoperative complications and no case required conversion to 20, 23, or 25 gauge instrumentation. A total of 6 sclerotomy sites (3.9%) were sutured at the conclusion of surgery. Post- operative complications included transient ocular hypertension in 3 eyes (5.8%) and transient hypotony in 2 eyes (3.9%). No cases of postoperative endophthalmitis, sclerotomy- related retinal tears, retinal detachment or choroidal detachments were encountered in the follow-up period.

Conclusions:

The 27 gauge 3PPV was well tolerated and safe with low rates of intraoperative and postoperative complications across varied surgical indications.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy